Alain Fischer (Collège de France) — June 15
Over the last 50 years, advances in molecular biology and genetics have made genome engineering possible.
This resulted, amongst many applications, in the medical development of gene therapy. The latter was first successfully used to treat rare inherited disorders of the immune system because of specificities of the immune cells (T lymphocytes). Based on a `gene addition’ strategy that requires viruses as gene carriers, gene therapy is now being used to treat several inherited disorders of the immune system while applications to immunotherapy of some cancers have also been successfully implemented. The next challenge will be to edit mutated genes to fix mutations rather than gene addition, a promising strategy that is still in its infancy.
Alain Fischer is a professor of immunology and a researcher in biology. He holds the chair of Experimental Medicine at the College de France. He is one of the founders and the current Director of the Institut Imagine, located in Hopital Necker and specialized in genetic diseases.
Alain’s research is devoted to identifying the genetic and molecular roots of hereditary diseases responsible for immune deficiencies. In 99, he obtained the first clinical successes in the world of gene therapies.
Alain’s contributions were rewarded with many prizes and distinctions such as the Sanofi/Pasteur prize, the Grand Prix Claude Bernard de la Ville de Paris, the Avery-Landsteiner prize, and the Grand Prix Inserm… He is a member of the French national Academy of Sciences and the national Academy of Medicine.